** Shares of weight-loss drug developers Eli Lilly LLY.N and U.S.-listed shares of Novo Nordisk NOVOb.CO fall between 1% and 3% in extended trading
** Lilly down 1.3% at $811.50, Novo falls 3.6% to $54.10
** U.S. President Donald Trump says that prices of weight-loss drugs, such as Novo's Ozempic, would be lowered
** "They'll be much lower," Trump told reporters during an event in the Oval Office
** Up to last close, LLY up 6.1% and U.S.-listed Novo down 34.8% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))